C
CytomX Therapeutics, Inc.
CTMX · NASDAQ · Healthcare · 731M
Closing price
$2.57
+4.05% · last session
Graham & Buffett's criteria
published figures · last financial year
Price / earningsP/E
—
Price / net assetsP/B
3.6×
Enterprise value / EBITDAEV/EBITDA
-22.0×
Free cash flow yieldFCF yield
-21.4%
Return on equityROE
-17.5%
Operating margin
-29.3%
Net debt / EBITDAbalance-sheet strength
0.5×
Interest coverage
—
How we read it
an educational summary · not advice
Figures provided for information and education — they do not constitute personalized investment advice. Investing carries a risk of capital loss.